Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011 (2011), Article ID 283137, 10 pages
http://dx.doi.org/10.4061/2011/283137
Review Article

The Cardiorenal Syndrome: Making the Connection

Division of Nephrology, Tufts Medical Center, 800 Washington Street, P.O. 391, Boston, MA 02111, USA

Received 18 August 2010; Accepted 17 September 2010

Academic Editor: Mitchell H. Rosner

Copyright © 2011 Gautham Viswanathan and Scott Gilbert. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. H. W. Tang and W. Mullens, “Cardiorenal syndrome in decompensated heart failure,” Heart, vol. 96, no. 4, pp. 255–260, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal syndromes: Report from the consensus conference of the acute dialysis quality initiative,” European Heart Journal, vol. 31, no. 6, pp. 703–711, 2010. View at Publisher · View at Google Scholar · View at PubMed
  3. J. J. V. McMurray and M. A. Pfeffer, “Heart failure,” Lancet, vol. 365, no. 9474, pp. 1877–1889, 2005. View at Publisher · View at Google Scholar · View at PubMed
  4. G. A. Haldeman, J. B. Croft, W. H. Giles, and A. Rashidee, “Hospitalization of patients with heart failure: national hospital discharge survey, 1985 to 1995,” American Heart Journal, vol. 137, no. 2, pp. 352–360, 1999. View at Publisher · View at Google Scholar · View at PubMed
  5. W. Rosamond, K. Flegal, K. Furie et al., “Heart disease and stroke statistics—2008 update: a report from the American heart association statistics committee and stroke statistics subcommittee,” Circulation, vol. 117, no. 4, pp. e25–e146, 2008. View at Publisher · View at Google Scholar · View at PubMed
  6. D. E. Forman, J. Butler, Y. Wang et al., “Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure,” Journal of the American College of Cardiology, vol. 43, no. 1, pp. 61–67, 2004. View at Publisher · View at Google Scholar
  7. D. Wencker, “Acute cardio-renal syndrome: progression from congestive heart failure to congestive kidney failure,” Current Heart Failure Reports, vol. 4, no. 3, pp. 134–138, 2007. View at Publisher · View at Google Scholar
  8. H. L. Hillege, A. R. J. Girbes, P. J. De Kam et al., “Renal function, neurohormonal activation, and survival in patients with chronic heart failure,” Circulation, vol. 102, no. 2, pp. 203–210, 2000. View at Google Scholar
  9. G. C. Fonarow, K. F. Adams Jr., W. T. Abraham, C. W. Yancy, and W. J. Boscardin, “Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis,” Journal of the American Medical Association, vol. 293, no. 5, pp. 572–580, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. K. Damman, G. Navis, A. A. Voors et al., “Worsening renal function and prognosis in heart failure: systematic review and meta-analysis,” Journal of Cardiac Failure, vol. 13, no. 8, pp. 599–608, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. S. S. Gottlieb, W. Abraham, J. Butler et al., “The prognostic importance of different definitions of worsening renal function in congestive heart failure,” Journal of Cardiac Failure, vol. 8, no. 3, pp. 136–141, 2002. View at Publisher · View at Google Scholar
  12. H. L. Hillege, D. Nitsch, M. A. Pfeffer et al., “Renal function as a predictor of outcome in a broad spectrum of patients with heart failure,” Circulation, vol. 113, no. 5, pp. 671–678, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. R. S. Bhatia, J. V. Tu, D. S. Lee et al., “Outcome of heart failure with preserved ejection fraction in a population-based study,” New England Journal of Medicine, vol. 355, no. 3, pp. 260–269, 2006. View at Publisher · View at Google Scholar · View at PubMed
  14. F. A. McAlister, J. Ezekowitz, M. Tonelli, and P. W. Armstrong, “Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study,” Circulation, vol. 109, no. 8, pp. 1004–1009, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. J. T. Heywood, G. C. Fonarow, M. R. Costanzo, V. S. Mathur, J. R. Wigneswaran, and J. Wynne, “High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database,” Journal of Cardiac Failure, vol. 13, no. 6, pp. 422–430, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. K. F. Adams Jr., G. C. Fonarow, C. L. Emerman et al., “Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE),” American Heart Journal, vol. 149, no. 2, pp. 209–216, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. D. L. Dries, D. V. Exner, M. J. Domanski, B. Greenberg, and L. W. Stevenson, “The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction,” Journal of the American College of Cardiology, vol. 35, no. 3, pp. 681–689, 2000. View at Publisher · View at Google Scholar
  18. T. D. J. Smilde, H. L. Hillege, A. A. Voors, P. H. J. Dunselman, and D. J. Van Veldhuisen, “Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction,” American Journal of Cardiology, vol. 94, no. 2, pp. 240–243, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. G. L. Smith, J. H. Lichtman, M. B. Bracken et al., “Renal impairment and outcomes in heart failure: systematic review and meta-analysis,” Journal of the American College of Cardiology, vol. 47, no. 10, pp. 1987–1996, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. R. W. Schrier and W. T. Abraham, “Hormones and hemodynamics in heart failure,” New England Journal of Medicine, vol. 341, no. 8, pp. 577–585, 1999. View at Publisher · View at Google Scholar · View at PubMed
  21. U. C. Brewster and M. A. Perazella, “The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease,” American Journal of Medicine, vol. 116, no. 4, pp. 263–272, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. T. D. Smilde, K. Damman, P. van der Harst et al., “Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure,” Clinical Research in Cardiology, vol. 98, no. 2, pp. 121–129, 2009. View at Publisher · View at Google Scholar · View at PubMed
  23. C. W. Yancy, M. Lopatin, L. W. Stevenson, T. De Marco, and G. C. Fonarow, “Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database,” Journal of the American College of Cardiology, vol. 47, no. 1, pp. 76–84, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. A. Nohria, V. Hasselblad, A. Stebbins et al., “Cardiorenal interactions: insights from the ESCAPE trial,” Journal of the American College of Cardiology, vol. 51, no. 13, pp. 1268–1274, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. J. D. Firth, A. E. G. Raine, and J. G. G. Ledingham, “Raised venous pressure: a direct cause of renal sodium retention in oedema?” Lancet, vol. 1, no. 8593, pp. 1033–1036, 1988. View at Google Scholar
  26. M. H. Maxwell, E. S. Breed, and I. L. Schwartz, “Renal venous pressure in chronic congestive heart failure,” The Journal of Clinical Investigation, vol. 29, no. 3, pp. 342–348, 1950. View at Google Scholar
  27. P. R. Kastner, J. E. Hall, and A. C. Guyton, “Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II,” The American Journal of Physiology, vol. 243, no. 3, pp. F260–F264, 1982. View at Google Scholar
  28. K. Damman, G. Navis, T. D. J. Smilde et al., “Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction,” European Journal of Heart Failure, vol. 9, no. 9, pp. 872–878, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. W. Mullens, Z. Abrahams, G. S. Francis et al., “Importance of venous congestion for worsening of renal function in advanced decompensated heart failure,” Journal of the American College of Cardiology, vol. 53, no. 7, pp. 589–596, 2009. View at Publisher · View at Google Scholar · View at PubMed
  30. K. Damman, V. M. van Deursen, G. Navis, A. A. Voors, D. J. van Veldhuisen, and H. L. Hillege, “Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease,” Journal of the American College of Cardiology, vol. 53, no. 7, pp. 582–588, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. W. Mullens, Z. Abrahams, H. N. Skouri et al., “Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?” Journal of the American College of Cardiology, vol. 51, no. 3, pp. 300–306, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. S. E. Bradley and G. P. Bradley, “The effect of increased intra-abdominal pressure on renal function in man,” The Journal of Clinical Investigation, vol. 26, no. 5, pp. 1010–1012, 1947. View at Google Scholar
  33. J. M. Doty, B. H. Saggi, H. J. Sugerman et al., “Effect of increased renal venous pressure on renal function,” Journal of Trauma, vol. 47, no. 6, pp. 1000–1003, 1999. View at Google Scholar
  34. I. A. Reid, “Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure,” American Journal of Physiology, vol. 262, no. 6, pp. E763–E778, 1992. View at Google Scholar
  35. M. Ruiz-Ortega, O. Lorenzo, and J. Egido, “Angiotensin III increases MCP-1 and activates NF-κB and AP-1 in cultured mesangial and mononuclear cells,” Kidney International, vol. 57, no. 6, pp. 2285–2298, 2000. View at Publisher · View at Google Scholar · View at PubMed
  36. K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, and R. W. Alexander, “Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells,” Circulation Research, vol. 74, no. 6, pp. 1141–1148, 1994. View at Google Scholar
  37. T. Chabrashvili, A. Tojo, M. L. Onozato et al., “Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney,” Hypertension, vol. 39, no. 2, pp. 269–274, 2002. View at Publisher · View at Google Scholar
  38. M. Ruiz-Ortega, C. Bustos, M. A. Hernández-Presa, O. Lorenzo, J. J. Plaza, and J. Egido, “Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis,” Journal of Immunology, vol. 161, no. 1, pp. 430–439, 1998. View at Google Scholar
  39. D. Schlöndorff, P. J. Nelson, B. Luckow, and B. Banas, “Chemokines and renal disease,” Kidney International, vol. 51, no. 3, pp. 610–621, 1997. View at Google Scholar
  40. T. Matsukawa, E. Gotoh, K. Minamisawa et al., “Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans,” American Journal of Physiology, vol. 261, no. 3, pp. R690–R696, 1991. View at Google Scholar
  41. G. Ligtenberg, P. J. Blankestijn, P. L. Oey et al., “Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure,” New England Journal of Medicine, vol. 340, no. 17, pp. 1321–1328, 1999. View at Publisher · View at Google Scholar · View at PubMed
  42. I. H. H. T. Klein, G. Ligtenberg, P. L. Oey, H. A. Koomans, and P. J. Blankestijn, “Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. 425–430, 2003. View at Publisher · View at Google Scholar
  43. S. Kim and H. Iwao, “Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases,” Pharmacological Reviews, vol. 52, no. 1, pp. 11–34, 2000. View at Google Scholar
  44. H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama, “The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease,” Pharmacological Reviews, vol. 59, no. 3, pp. 251–287, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. A. T. Whaley-Connell, N. A. Chowdhury, M. R. Hayden et al., “Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat,” American Journal of Physiology, vol. 291, no. 6, pp. F1308–F1314, 2006. View at Publisher · View at Google Scholar · View at PubMed
  46. A. Bataineh and L. Raij, “Angiotensin II, nitric oxide, and end-organ damage in hypertension,” Kidney International, Supplement, vol. 54, no. 68, pp. S14–S19, 1998. View at Google Scholar
  47. L. De Nicola, R. C. Blantz, F. B. Gabbai, and S. J. Khang, “Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat,” Journal of Clinical Investigation, vol. 89, no. 4, pp. 1248–1256, 1992. View at Google Scholar
  48. J. P. Tolins, R. M. J. Palmer, S. Moncada, and L. Raij, “Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses,” American Journal of Physiology, vol. 258, no. 3, pp. H655–H662, 1990. View at Google Scholar
  49. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,” Lancet, vol. 339, no. 8793, pp. 572–575, 1992. View at Publisher · View at Google Scholar
  50. J. T. Kielstein, S. M. Bode-Böger, G. Klein, S. Graf, H. Haller, and D. Fliser, “Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure,” European Journal of Clinical Investigation, vol. 33, no. 5, pp. 370–375, 2003. View at Publisher · View at Google Scholar
  51. G. L. Bakris and R. N. Re, “Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells,” American Journal of Physiology, vol. 264, no. 6, pp. F937–F942, 1993. View at Google Scholar
  52. H. Hayakawa and L. Raij, “Nitric oxide synthase activity and renal injury in genetic hypertension,” Hypertension, vol. 31, no. 1, pp. 266–270, 1998. View at Google Scholar
  53. K. E. Jie, M. C. Verhaar, M.-J. M. Cramer et al., “Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors,” American Journal of Physiology, vol. 291, no. 5, pp. F932–F944, 2006. View at Publisher · View at Google Scholar · View at PubMed
  54. D. S. Silverberg, D. Wexler, M. Blum et al., “The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations,” Journal of the American College of Cardiology, vol. 35, no. 7, pp. 1737–1744, 2000. View at Publisher · View at Google Scholar
  55. G. A. J. Riegger, G. Liebau, and K. Kochsiek, “Antidiuretic hormone in congestive heart failure,” American Journal of Medicine, vol. 72, no. 1, pp. 49–52, 1982. View at Google Scholar
  56. M. A. Konstam, M. Gheorghiade, J. C. Burnett Jr. et al., “Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial,” Journal of the American Medical Association, vol. 297, no. 12, pp. 1319–1331, 2007. View at Publisher · View at Google Scholar · View at PubMed
  57. K. Damman, D. J. Van Veldhuisen, G. Navis et al., “Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate,” Heart, vol. 96, no. 16, pp. 1297–1302, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. V. Witko-Sarsat, M. Friedlander, T. N. Khoa et al., “Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure,” Journal of Immunology, vol. 161, no. 5, pp. 2524–2532, 1998. View at Google Scholar
  59. J. T. Norman and L. G. Fine, “Intrarenal oxygenation in chronic renal failure,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 10, pp. 989–996, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. K. Damman, P. R. Kalra, and H. Hillege, “Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure,” Journal of Renal Care, vol. 36, supplement 1, pp. 18–26, 2010. View at Publisher · View at Google Scholar · View at PubMed
  61. M. Haase, R. Bellomo, P. Devarajan, P. Schlattmann, and A. Haase-Fielitz, “Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1012–1024, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, “Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury,” Kidney International, vol. 62, no. 1, pp. 237–244, 2002. View at Publisher · View at Google Scholar · View at PubMed
  63. S. G. Coca, R. Yalavarthy, J. Concato, and C. R. Parikh, “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review,” Kidney International, vol. 73, no. 9, pp. 1008–1016, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. S. Herget-Rosenthal, J. A. E. van Wijk, M. Bröcker-Preuss, and A. Bökenkamp, “Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate,” Clinical Biochemistry, vol. 40, no. 13-14, pp. 946–951, 2007. View at Publisher · View at Google Scholar · View at PubMed
  65. P. Devarajan, “Emerging biomarkers for acute kidney injury,” Clinical Laboratory International, April/ May 2009. View at Google Scholar
  66. C. V. Leier, “Renal roadblock in managing low output heart failure,” Critical Care Medicine, vol. 32, no. 5, pp. 1228–1229, 2004. View at Publisher · View at Google Scholar
  67. “Determining Optimal Dose and Duration of Diuretic Treatment in People with Acute Heart Failure (The DOSE-AHF Study),” August 2010, http://clinicaltrials.gov/ct2/show/NCT00577135.
  68. J. D. Sackner-Bernstein, H. A. Skopicki, and K. D. Aaronson, “Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure,” Circulation, vol. 111, no. 12, pp. 1487–1491, 2005. View at Publisher · View at Google Scholar · View at PubMed
  69. D. J. Wang, T. C. Dowling, D. Meadows et al., “Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine,” Circulation, vol. 110, no. 12, pp. 1620–1625, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. A. F. Hernandez, C. M. O'Connor, R. C. Starling et al., “Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF),” American Heart Journal, vol. 157, no. 2, pp. 271–277, 2009. View at Publisher · View at Google Scholar · View at PubMed
  71. L. C. Costello-Boerrigter, W. B. Smith, G. Boerrigter et al., “Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure,” American Journal of Physiology, vol. 290, no. 2, pp. F273–F278, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. M. M. Givertz, B. M. Massie, T. K. Fields, L. L. Pearson, and H. C. Dittrich, “The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance,” Journal of the American College of Cardiology, vol. 50, no. 16, pp. 1551–1560, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. B. A. Bart, A. Boyle, A. J. Bank et al., “Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial,” Journal of the American College of Cardiology, vol. 46, no. 11, pp. 2043–2046, 2005. View at Publisher · View at Google Scholar · View at PubMed
  74. M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al., “Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure,” Journal of the American College of Cardiology, vol. 49, no. 6, pp. 675–683, 2007. View at Publisher · View at Google Scholar · View at PubMed
  75. B. A. Bart, M. M. Walsh, D. Blake, and S. R. Goldsmith, “Ultrafiltration for cardiorenal syndrome,” Journal of Cardiac Failure, vol. 14, no. 6, pp. 531–532, 2008. View at Publisher · View at Google Scholar · View at PubMed
  76. “Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),” August 2010, http://clinicaltrials.gov/ct2/show/NCT00608491.
  77. G. M. Felker, R. L. Benza, A. B. Chandler et al., “Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 997–1003, 2003. View at Publisher · View at Google Scholar
  78. M. B. Yilmaz, K. Yalta, C. Yontar et al., “Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine,” Cardiovascular Drugs and Therapy, vol. 21, no. 6, pp. 431–435, 2007. View at Publisher · View at Google Scholar · View at PubMed
  79. A. Mebazaa, M. S. Nieminen, M. Packer et al., “Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial,” Journal of the American Medical Association, vol. 297, no. 17, pp. 1883–1891, 2007. View at Publisher · View at Google Scholar · View at PubMed